Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
Status: Enrolling
Updated:  8/18/2013
outpatient pulmonary clinics, University of Maryland Medical school hospital
mi
from
Baltimore, MD
Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
Status: Enrolling
Updated: 8/18/2013
outpatient pulmonary clinics, University of Maryland Medical school hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
*See Various Dept.'s*, AZ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
*See Various Dept.'s*, AZ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Chandler, AZ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fresno, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fresno, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fullerton, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Boulder, CO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Boulder, CO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Wheat Ridge, CO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lynn Haven, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lynn Haven, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Miami, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Port Orange, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Port Orange, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Winter Park, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Conyers, GA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Conyers, GA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
River Forest, IL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
River Forest, IL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Skokie, IL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Skokie, IL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Newburgh, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Newburgh, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Iowa City, IA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lexington, KY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lexington, KY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Sunset, LA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Sunset, LA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
Fall River, MA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
Fall River, MA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
North Dartmouth, MA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Minneapolis, MN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Plymouth, MN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Plymouth, MN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Saint Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Charles, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fremont, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fremont, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lincoln, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Omaha, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Papillion, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Papillion, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cherry Hill, NJ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Great Neck, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Massapequa, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Massapequa, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
New Windsor, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
New Windsor, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
New York, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
New York, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Syracuse, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Charlotte, NC
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Columbus, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials